In patients with chronic lymphocytic leukemia (CLL), regular treatment with immunoglobulin replacement therapy was not associated with a reduced risk of serious infections requiring hospitalization, ...

Many patients with chronic lymphocytic leukemia (CLL) are treated with two- or three-drug regimens, but for some patients just one drug may be enough. Particularly for older patients or those who are ...

Combination therapies for chronic lymphocytic leukemia (CLL) offer improved depth of response and potentially longer survival times compared with single-agent treatments. They target different ...

The FDA has granted fast track designation to UB-VV111 for the treatment of relapsed/refractory large B-cell lymphoma (LBCL) following 2 or more prior lines of therapy and relapsed/refractory chronic ...